Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
577.44B
Market cap577.44B
Price-Earnings ratio
21.72
Price-Earnings ratio21.72
Dividend yield
2.17%
Dividend yield2.17%
Average volume
9.21M
Average volume9.21M
High today
High today
Low today
Low today
Open price
$241.54
Open price$241.54
Volume
0.00
Volume0.00
52 Week high
$251.71
52 Week high$251.71
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

Johnson & Johnson(JNJ) stock is priced at $245.30, giving the company a market capitalization of 577.44B. It carries a P/E multiple of 21.72 and pays a dividend yield of 2.2%.

On 2026-03-06, Johnson & Johnson(JNJ) shares started trading at $241.54, with intraday highs of — and lows of —.

Trading volume for Johnson & Johnson(JNJ) stock has reached 0, versus its average volume of 9.21M.

The stock's 52-week range extends from a low of $141.50 to a high of $251.71.

The stock's 52-week range extends from a low of $141.50 to a high of $251.71.

JNJ News

TipRanks 15h
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress

The latest announcement is out from Contineum Therapeutics, Inc. Class A ( (CTNM) ). Contineum Therapeutics amended its existing at-the-market equity program w...

TipRanks 16h
Johnson & Johnson confirms FDA approval of Tecvayli-Darzalex Faspro combination

Johnson & Johnson announced that the U.S. Food and Drug Administration approved Tecvayli plus Darzalex Faspro for the treatment of adults with relapsed or refra...

Simply Wall St 16h
Is It Time To Reassess Johnson & Johnson After Strong Multi Year Share Price Gains

If you are wondering whether Johnson & Johnson is trading at a fair price today, you are not alone. The mix of a strong brand and changing headlines has many in...

Is It Time To Reassess Johnson & Johnson After Strong Multi Year Share Price Gains

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
35.7%
Sell
7.1%

More JNJ News

Nasdaq 21h
Interesting JNJ Put And Call Options For April 24th

Investors in Johnson & Johnson (Symbol: JNJ) saw new options begin trading today, for the April 24th expiration. At Stock Options Channel , our YieldBoost formu...

Interesting JNJ Put And Call Options For April 24th
TipRanks 1d
Johnson & Johnson price target raised to $250 from $225 at JPMorgan

JPMorgan raised the firm’s price target on Johnson & Johnson to $250 from $225 and keeps a Neutral rating on the shares. The firm cites its increased Tremfya es...

Simply Wall St 2d
Should FDA Fast Track Status for Nipocalimab in Lupus Reshape Johnson & Johnson’s Immunology Ambitions?

Johnson & Johnson recently announced that the U.S. FDA granted Fast Track designation to nipocalimab as a potential treatment for adults with systemic lupus ery...

Should FDA Fast Track Status for Nipocalimab in Lupus Reshape Johnson & Johnson’s Immunology Ambitions?
24/7 Wall St. 2d
Top 3 Dividend Aristocrat Stocks to Buy for Strong Returns in 2026

Top 3 Dividend Aristocrat Stocks to Buy for Strong Returns in 2026 Quick Read Exxon Mobil (XOM) is up 26% year-to-date and Johnson & Johnson (JNJ) surged 68% f...

Top 3 Dividend Aristocrat Stocks to Buy for Strong Returns in 2026
Nasdaq 2d
Only Eight Dow Components With Recent Insider Buying, JNJ is One of Them

The officers and directors of a company tend to have a unique inside view into the business, so when these insiders make purchases, investors are wise to take n...

Only Eight Dow Components With Recent Insider Buying, JNJ is One of Them
Nasdaq 3d
Immunology, Neuroscience Step Up as Key Growth Engines for J&J

Johnson & Johnson JNJ is one of the key pharmaceutical players in the oncology segment, with its Oncology segment comprising around 27% of total revenues and 42...

Immunology, Neuroscience Step Up as Key Growth Engines for J&J
Simply Wall St 3d
Johnson & Johnson Valuation Check As New Prostate Cancer Therapy Data Progresses

Johnson & Johnson (JNJ) is back in focus after releasing preliminary Phase 1b data on pasritamig plus docetaxel in metastatic castration-resistant prostate canc...

Johnson & Johnson Valuation Check As New Prostate Cancer Therapy Data Progresses

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.